The International Working Group (IWG) recently proposed the revised diagnostic criteria for Alzheimer’s disease (AD) to define and refine several types of AD, and to reclassify AD-related biomarkers into diagnostic and progression markers, but its performance is not known.
Objective:
This study was designed to describe the application of the revised IWG criteria in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset, and to ascertain whether diagnostic and progression markers show significant differences in their relationships to AD severity and progression.
Methods:
Based on the requirements of the refined criteria, 857 ADNI subjects with memory evaluation and at least one pathophysiological marker (CSF or amyloid imaging biomarkers) were eligible and reclassified in this study, and we calculated the associations of diagnostic (CSF and amyloid PET) and progression markers (MRI and fluorodeoxyglucose-PET) with AD severity and progression respectively.
Results:
The majority (84.2% ) of ADNI AD group (n = 117) and 173 MCI (37.4% ) subjects in ADNI met the definition of typical AD; and 105 cognitively normal (41.0% ) individuals were diagnosed as asymptomatic AD. Furthermore, diagnostic and progression markers showed significant differences when correlated to AD severity and progression.
Conclusion:
A large proportion of AD dementia subjects were categorized as typical AD, and the revised criteria could identify typical AD from MCI status as well as asymptomatic AD at the asymptomatic stage. Moreover, the significant differences between diagnostic and progression markers further supported the new biomarkers categorization in the refined criteria.
VisserPJ, VerheyF, KnolDL, ScheltensP, WahlundLO, Freund-LeviY, TsolakiM, MinthonL, WallinAK, HampelH, BurgerK, PirttilaT, SoininenH, RikkertMO, VerbeekMM, SpiruL, BlennowK (2009) Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol8, 619–627.
BlennowK, HampelH, WeinerM, ZetterbergH (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol6, 131–144.
5.
WhitwellJL, DicksonDW, MurrayME, WeigandSD, TosakulwongN, SenjemML, KnopmanDS, BoeveBF, ParisiJE, PetersenRC, JackCRJr., JosephsKA (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: A case-control study. Lancet Neurol11, 868–877.
6.
FrisoniGB, PievaniM, TestaC, SabattoliF, BrescianiL, BonettiM, BeltramelloA, HayashiKM, TogaAW, ThompsonPM (2007) The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain130, 720–730.
7.
DickersonBC, WolkDA (2012) MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology78, 84–90.
8.
LehmannM, GhoshPM, MadisonC, LaforceRJr, Corbetta-RastelliC, WeinerMW, GreiciusMD, SeeleyWW, Gorno-TempiniML, RosenHJ, MillerBL, JagustWJ, RabinoviciGD (2013) Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain136, 844–858.
9.
EwersM, InselPS, SternY, WeinerMW (2013) Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology80, 1194–1201.
10.
LeinonenV, RinneJO, VirtanenKA, EskolaO, RummukainenJ, HuttunenJ, vonUZFM, NergO, KoivistoAM, RinneJ, JaaskelainenJE, BuckleyC, SmithA, JonesPA, SherwinP, FarrarG, McLainR, KailajarviM, HeurlingK, GrachevID (2013) Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol20, 1043–1052.
11.
JackCRJr, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
KoivunenJ, ScheininN, VirtaJR, AaltoS, VahlbergT, NagrenK, HelinS, ParkkolaR, ViitanenM, RinneJO (2011) Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology76, 1085–1090.
14.
RoeCM, FaganAM, GrantEA, HassenstabJ, MoulderKL, MaueDD, SutphenCL, BenzingerTL, MintunMA, HoltzmanDM, MorrisJC (2013) Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology80, 1784–1791.
15.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
16.
JackCRJr, AlbertMS, KnopmanDS, McKhannGM, SperlingRA, CarrilloMC, ThiesB, PhelpsCH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 257–262.
17.
LoweVJ, PellerPJ, WeigandSD, MontoyaQC, TosakulwongN, VemuriP, SenjemML, JordanL, JackCRJr, KnopmanD, PetersenRC (2013) Application of the NationalInstitute on Aging-Alzheimer’s Association AD criteria to ADNI. Neurology80, 2130–2137.
18.
PetersenRC, AisenP, BoeveBF, GedaYE, IvnikRJ, KnopmanDS, MielkeM, PankratzVS, RobertsR, RoccaWA, WeigandS, WeinerM, WisteH, JackCRJr (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol74, 199–208.
19.
JackCRJr, KnopmanDS, WeigandSD, WisteHJ, VemuriP, LoweV, KantarciK, GunterJL, SenjemML, IvnikRJ, RobertsRO, RoccaWA, BoeveBF, PetersenRC (2012) An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol71, 765–775.
BrayneC (2014) A population perspective on the IWG-2 research diagnostic criteria for Alzheimer’s disease. Lancet Neurol13, 532–534.
22.
WeinerMW, VeitchDP, AisenPS, BeckettLA, CairnsNJ, GreenRC, HarveyD, JackCR, JagustW, LiuE, MorrisJC, PetersenRC, SaykinAJ, SchmidtME, ShawL, ShenL, SiuciakJA, SoaresH, TogaAW, TrojanowskiJQ (2013) The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement9, e111–e194.
23.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
24.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
25.
VosSJ, XiongC, VisserPJ, JasielecMS, HassenstabJ, GrantEA, CairnsNJ, MorrisJC, HoltzmanDM, FaganAM (2013) Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol12, 957–965.
TrojanowskiJQ, VandeersticheleH, KoreckaM, ClarkCM, AisenPS, PetersenRC, BlennowK, SoaresH, SimonA, LewczukP, DeanR, SiemersE, PotterWZ, WeinerMW, JackCRJr, JagustW, TogaAW, LeeVM, ShawLM (2010) Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement6, 230–238.
28.
ZhangD, WangY, ZhouL, YuanH, ShenD (2011) Multimodal classification of Alzheimer’s disease and mild cognitive impairment. Neuroimage55, 856–867.
29.
LoRY, HubbardAE, ShawLM, TrojanowskiJQ, PetersenRC, AisenPS, WeinerMW, JagustWJ (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neurol68, 1257–1266.
30.
FotuhiM, DoD, JackC (2012) Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol8, 189–202.
31.
denHT, vandLF, KoudstaalPJ, HofmanA, vandLA, KrestinGP, NiessenWJ, BretelerMM (2010) A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain133, 1163–1172.
32.
BohnenNI, DjangDS, HerholzK, AnzaiY, MinoshimaS (2012) Effectiveness and safety of 18F-FDG PET in theevaluation of dementia: A review of the recent literature. J Nucl Med53, 59–71.
DodgeHH, ZhuJ, HarveyD, SaitoN, SilbertLC, KayeJA, KoeppeRA, AlbinRL (2014) Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. Alzheimers Dement10, 690–703.
35.
BouwmanFH, VerweyNA, KleinM, KokA, BlankensteinMA, SluimerJD, BarkhofF, van der FlierWM, ScheltensP (2010) New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population. Dement Geriatr Cogn Disord30, 1–7.
36.
MolinuevoJL, RamiL (2013) Applying the IWG research criteria in clinical practice: Feasibility and ethical issues. Med Clin North Am97, 477–484.
